Q3 2021 13F Holders as of 9/30/2021
-
Type / Class
-
Equity / Common Stock
-
Shares outstanding
-
70.9M
-
Number of holders
-
111
-
Total 13F shares, excl. options
-
34.5M
-
Shares change
-
+2.22M
-
Total reported value, excl. options
-
$1.54B
-
Value change
-
+$109M
-
Number of buys
-
68
-
Number of sells
-
-32
-
Price
-
$44.68
Significant Holders of C4 Therapeutics, Inc. - Common Stock (CCCC) as of Q3 2021
126 filings reported holding CCCC - C4 Therapeutics, Inc. - Common Stock as of Q3 2021.
C4 Therapeutics, Inc. - Common Stock (CCCC) has 111 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 34.5M shares
of 70.9M outstanding shares and own 48.61% of the company stock.
Largest 10 shareholders include PRICE T ROWE ASSOCIATES INC /MD/ (3.96M shares), BlackRock Inc. (3.16M shares), RTW INVESTMENTS, LP (2.49M shares), PERCEPTIVE ADVISORS LLC (2.26M shares), VANGUARD GROUP INC (1.94M shares), STATE STREET CORP (1.66M shares), Bain Capital Life Sciences Investors, LLC (1.64M shares), ArrowMark Colorado Holdings LLC (1.51M shares), RA CAPITAL MANAGEMENT, L.P. (1.38M shares), and WASATCH ADVISORS INC (1.34M shares).
This table shows the top 111 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.